Celiac Disease – Pipeline Review, Q1 2011
Celiac Disease - Pipeline Review, Q1 2011
Reference Code: GMDHC141IDB
Publication Date: February 2011
Celiac Disease – Pipeline Review, Q1 2011 GMDHC141IDB / Pub FEB 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Celiac Disease – Pipeline Review, Q1 2011
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables ............................................................................................................................................................................................................ 4
List of Figures ........................................................................................................................................................................................................... 4
Introduction .............................................................................................................................................................................................................. 5
Global Markets Direct Report Coverage ............................................................................................................................................................. 5
Celiac Disease Overview .......................................................................................................................................................................................... 6
Therapeutics Development ....................................................................................................................................................................................... 7
An Overview of Pipeline Products for Celiac Disease ......................................................................................................................................... 7
Celiac Disease Therapeutics under Development by Companies ............................................................................................................................. 9
Celiac Disease Therapeutics under Investigation by Universities/Institutes ..............................................................................................................10
Mid Clinical Stage Products .....................................................................................................................................................................................11
Comparative Analysis .......................................................................................................................................................................................11
Early Clinical Stage Products ..................................................................................................................................................................................12
Comparative Analysis .......................................................................................................................................................................................12
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................13
Comparative Analysis .......................................................................................................................................................................................13
Companies Involved in Celiac Disease Therapeutics Development .........................................................................................................................14
GlaxoSmithKline plc ..........................................................................................................................................................................................14
Alba Therapeutics Corporation ..........................................................................................................................................................................14
ActogeniX NV....................................................................................................................................................................................................15
Artielle ImmunoTherapeutics, Inc. .....................................................................................................................................................................15
Alvine Pharmaceuticals, Inc. .............................................................................................................................................................................16
Avaxia Biologics, Inc. ........................................................................................................................................................................................16
FunZyme BioTechnologies S.A. ........................................................................................................................................................................17
Nexpep .............................................................................................................................................................................................................17
Universities/Institutes Involved in Celiac Disease Therapeutics Development..........................................................................................................18
Celiac Disease - Therapeutics Assessment .............................................................................................................................................................19
Assessment by Monotherapy Products .............................................................................................................................................................19
Assessment by Route of Administration ............................................................................................................................................................20
Assessment by Molecule Type ..........................................................................................................................................................................22
Discontinued Products.............................................................................................................................................................................................24
Celiac Disease - Featured News .......................................................................................................................................................................25
1. Nov 02, 2010: Alvine Pharmaceuticals’ ALV003 Named A Top 10 Inflammatory/Autoimmune Project To Watch By Windhover..............25
2. Oct 29, 2009: Alvine Pharmaceuticals Reports Positive Results With AlV003 In Phase 1 Trial Of Therapy In Development For Celiac
Disease ......................................................................................................................................................................................................25
3. Aug 25, 2009: Alvine Initiates Enrollment in Phase 2a Clinical Trial of ALV003 for Use in the Treatment of Celiac Disease ....................26
4. Mar 19, 2009: Numerate Awarded Phase 1 NIH Grant to Support Design of New Therapies for Celiac Disease .....................................26
5. Mar 17, 2009: Alba Therapeutics Corporation Announces the Next Clinical Trial of its Lead Compound, Larazotide Acetate ..................27
6. Nov 11, 2008: Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate
for Treatment of Active Celiac Disease .......................................................................................................................................................27
7. Oct 07, 2008: Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual
Scientific Meeting........................................................................................................................................................................................27
8. May 20, 2008: Alba Therapeutics Announces The Presentation Of Results Of A Phase IIa Clinical Trial For Larazotide Acetate For The
Treatment Of Celiac Disease ......................................................................................................................................................................29
9. May 16, 2008: Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for
Larazotide Acetate for the Treatment of Active Celiac Disease ..................................................................................................................30
10. Feb 21, 2008: Alvine Pharmaceuticals Obtains Patents for Celiac Disease Therapies ..........................................................................31
Appendix .................................................................................................................................................................................................................32
Celiac Disease – Pipeline Review, Q1 2011